These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 18586927

  • 1. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA.
    J Clin Oncol; 2008 Mar 01; 26(7):1040-50. PubMed ID: 18227526
    [Abstract] [Full Text] [Related]

  • 5. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep 01; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 6. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
    Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176
    [Abstract] [Full Text] [Related]

  • 7. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K.
    J Am Coll Cardiol; 2007 Feb 20; 49(7):753-62. PubMed ID: 17306703
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG.
    J Natl Cancer Inst; 2006 Feb 15; 98(4):273-84. PubMed ID: 16478746
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
    Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF.
    J Clin Oncol; 2008 May 10; 26(14):2342-9. PubMed ID: 18467726
    [Abstract] [Full Text] [Related]

  • 10. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 10; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 11. Treatment of anemia with darbepoetin alfa in systolic heart failure.
    Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, RED-HF Committees, RED-HF Investigators.
    N Engl J Med; 2013 Mar 28; 368(13):1210-9. PubMed ID: 23473338
    [Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep 28; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 14. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W.
    Clin Lung Cancer; 2011 Jan 03; 12(1):62-9. PubMed ID: 21273182
    [Abstract] [Full Text] [Related]

  • 15. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 16. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Feb 15; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 15; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 18. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Jun 15; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 19. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.
    Am J Kidney Dis; 2013 Feb 15; 61(2):238-46. PubMed ID: 23159232
    [Abstract] [Full Text] [Related]

  • 20. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr 15; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.